Twist Bioscience (NASDAQ:TWST) Price Target Cut to $40.00 by Barclays Analysts
Twist Biosciences (NASDAQ: TWST – Get a rating) saw its target price drop by Barclays from $60.00 to $40.00 in a research note released Monday to investors, Fly reports. BarclaysThe price target of suggests a potential upside of 27.43% from the current stock price.
Other equity research analysts have also recently released reports on the company. Goldman Sachs Group lowered its price target on Twist Bioscience from $105.00 to $55.00 and set a “neutral” rating on the stock in a Wednesday, April 13 research report. Robert W. Baird raised his target price on Twist Bioscience shares from $70.00 to $43.00 in a report on Friday. Zacks Investment Research upgraded Twist Bioscience shares from a “sell” rating to a “hold” rating in a Thursday, March 10, report. Finally, SVB Leerink lowered its price target on Twist Bioscience shares from $110.00 to $70.00 and set a “market performance” rating on the stock in a Monday, February 7 report. Three analysts rated the stock with a hold rating and three gave the company a buy rating. According to MarketBeat.com, Twist Bioscience has a consensus rating of “Buy” and a consensus price target of $52.00.
Shares of TWST opened at $31.39 on Monday. Twist Bioscience has a 1 year minimum of $28.21 and a 1 year maximum of $139.99. The stock’s 50-day moving average price is $43.75 and its two-hundred-day moving average price is $68.75.
Twist Biosciences (NASDAQ: TWST – Get a rating) last announced its quarterly results on Thursday, May 5. The company reported ($1.13) earnings per share for the quarter, beating analyst consensus estimates of ($1.26) by $0.13. The company posted revenue of $48.13 million for the quarter, versus a consensus estimate of $45.25 million. Twist Bioscience had a negative net margin of 114.96% and a negative return on equity of 31.94%. Twist Bioscience revenue for the quarter increased 54.2% year over year. During the same period last year, the company posted EPS of ($0.78). As a group, stock analysts predict that Twist Bioscience will post earnings per share of -4.97 for the current year.
In other Twist Bioscience news, an Insider Guillaume Banyai sold 1,280 shares of Twist Bioscience in a trade on Tuesday, February 22. The shares were sold at an average price of $52.66, for a total value of $67,404.80. The sale was disclosed in an SEC filing, which is available via this hyperlink. Additionally, Chief Financial Officer James M. Thorburn sold 6,620 shares in a trade dated Thursday, April 14. The stock was sold at an average price of $42.85, for a total transaction of $283,667.00. Following the transaction, the CFO now owns 46,688 shares of the company, valued at $2,000,580.80. Disclosure of this sale can be found here. In the past ninety days, insiders have sold 21,237 shares of the company valued at $1,077,325. Insiders hold 3.10% of the shares of the company.
A number of institutional investors and hedge funds have recently increased or reduced their stakes in the stock. Los Angeles Capital Management LLC increased its position in Twist Bioscience by 54.0% during the first quarter. Los Angeles Capital Management LLC now owns 5,705 shares of the company valued at $282,000 after purchasing an additional 2,000 shares in the last quarter. Nikko Asset Management Americas Inc. increased its stake in shares of Twist Bioscience by 1.1% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 2,376,285 shares of the company worth $107,622,000 after purchasing an additional 25,028 shares last quarter. New York State Common Retirement Fund increased its equity stake in Twist Bioscience by 18.1% during Q1. The New York State Common Retirement Fund now owns 51,776 shares of the company worth $2,557,000 after purchasing an additional 7,918 shares in the last quarter. California Public Employees Retirement System increased its equity stake in Twist Bioscience by 1.7% in Q1. California Public Employees Retirement System now owns 96,361 shares of the company valued at $4,758,000 after purchasing 1,618 additional shares in the last quarter. Finally, State of Michigan Retirement System increased its stake in Twist Bioscience shares by 188.1% in the first quarter. State of Michigan Retirement System now owns 153,172 shares of the company valued at $7,564,000 after purchasing an additional 100,000 shares in the last quarter.
Twist Bioscience Company Profile (Get a rating)
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA products. The Company’s DNA synthesis platform enables the manufacture of synthetic DNA by writing DNA onto a silicon chip. It offers synthetic DNA products, including synthetic genes, sample preparation tools, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. .
Get news and reviews for Twist Bioscience Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Twist Bioscience and related companies with MarketBeat.com’s free daily email newsletter.